It’s another one gone and another one gone for Amgen, as the pharmaceutical giant reported the latest clinical stoppage for a bispecific T-cell engager, or BiTE, therapy.
Amgen has stopped enrolling acute myeloid leukemia patients in a phase 1 clinical trial of its half-life extended FLT3 BiTE therapy AMG 427. News of the stoppage comes months after Amgen hit pause on a clutch of other BiTE clinical trials.
AMG 427 was moved into a phase 1 study in 2018. Amgen last week updated the ClinicalTrials.gov listing for the therapy to “active, not recruiting” without providing an explanation for the decision to stop enrolling new patients.